---
title: "BioCardia | 10-Q: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286562375.md"
datetime: "2026-05-15T12:08:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286562375.md)
  - [en](https://longbridge.com/en/news/286562375.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286562375.md)
---

# BioCardia | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.21.

EBIT: As of FY2026 Q1, the actual value is USD -2.273 M.

BioCardia, Inc. manages its operations as a single segment, therefore no segmented financial metrics are reported .

#### Operational Metrics

-   **Net Loss**: The net loss for the three months ended March 31, 2026, was -$2,259,000, compared to -$2,712,000 for the three months ended March 31, 2025 .
-   **Research and Development Expenses**: Research and development expenses decreased to $1,235,000 for the three months ended March 31, 2026, from $1,530,000 for the same period in 2025, primarily due to the closeout of the CardiAMP Heart Failure Trial .
-   **Selling, General and Administrative Expenses**: Selling, general and administrative expenses decreased to $1,031,000 for the three months ended March 31, 2026, from $1,196,000 for the same period in 2025, mainly due to lower professional service fees .
-   **Operating Loss**: The operating loss was -$2,266,000 for the three months ended March 31, 2026, compared to -$2,726,000 for the three months ended March 31, 2025 .
-   **Other Income, Net**: Total other income, net, was $7,000 for the three months ended March 31, 2026, compared to $14,000 for the same period in 2025 .
-   **Net Loss per Share, Basic and Diluted**: Net loss per share was -$0.21 for the three months ended March 31, 2026, compared to -$0.59 for the three months ended March 31, 2025 .
-   **Weighted-Average Shares**: Weighted-average shares used in computing net loss per share were 10,812,419 for the three months ended March 31, 2026, and 4,635,764 for the three months ended March 31, 2025 .
-   **Accumulated Deficit**: As of March 31, 2026, the accumulated deficit was approximately -$170,608,000 .

#### Cash Flow

-   **Net Cash Used in Operating Activities**: Net cash used in operating activities was -$1,659,000 for the three months ended March 31, 2026, compared to -$1,618,000 for the three months ended March 31, 2025, primarily due to the timing of payments to suppliers .
-   **Net Cash Used in Investing Activities**: Net cash used in investing activities was -$3,000 for the three months ended March 31, 2026, compared to $0 for the same period in 2025 .
-   **Net Cash Provided by Financing Activities**: Net cash provided by financing activities was $117,000 for the three months ended March 31, 2026, and $196,000 for the three months ended March 31, 2025, primarily from the sale of common stock offset by issuance costs .
-   **Cash and Cash Equivalents**: As of March 31, 2026, cash and cash equivalents were $951,000, a decrease from $2,496,000 as of December 31, 2025 .

#### Unique Metrics

-   **Common Shares Sold (ATM)**: 184,725 shares were sold under the At-the-Market (ATM) offering for the three months ended March 31, 2026, compared to 81,274 shares for the same period in 2025 .
-   **Gross Proceeds (ATM)**: Gross proceeds from ATM sales were $225,000 for the three months ended March 31, 2026, compared to $212,000 for the same period in 2025 .
-   **Associated Issuance Costs (ATM)**: Associated issuance costs for ATM sales were $40,000 for the three months ended March 31, 2026, compared to $27,000 for the same period in 2025 .
-   **Remaining ATM Capacity**: As of March 31, 2026, approximately $5.1 million of common stock may still be sold under the Sales Agreement .

#### Future Outlook and Strategy

BioCardia, Inc. anticipates continued operating losses and negative cash flows for the next several years, with current cash and cash equivalents insufficient to fund operations beyond June 2026 . The company plans to raise additional capital through debt, equity, or collaboration arrangements to fund future operations and advance its therapeutic candidates . Regulatory progress is being made for the CardiAMP Cell Therapy System in Japan and with the FDA, with the FDA recommending continuation of the CardiAMP HF II trial as a confirmatory study .

### Related Stocks

- [BCDA.US](https://longbridge.com/en/quote/BCDA.US.md)

## Related News & Research

- [Key facts: CardiAMP advances in US, Japan; FDA flags two Helix paths](https://longbridge.com/en/news/286637684.md)
- [BioCardia Q1 net loss narrows as expenses decline](https://longbridge.com/en/news/286562369.md)
- [Sangoma Announces Third Quarter Fiscal 2026 Results | SANG Stock News](https://longbridge.com/en/news/286317217.md)
- [Electro-Sensors GAAP EPS of -$0.03, revenue of $2.6M](https://longbridge.com/en/news/286518577.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)